BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $53 to $65.
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $53 to $65.